Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete ...
Our sustainability reporting is updated regularly and aligned with our policies, practices and data. We continue to improve our data collection processes and reporting of environmental, social and ...
 in Clinical Trials Compared to Those on Placebo As a ...
Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands Commercial execution and late-stage pipeline investments on schedule, ...
The four-year artificial intelligence (AI) program demonstrates how ‘a true spirit of collaboration’ can lead to breakthroughs in drug research and development. *The four-year artificial intelligence ...
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with ...
OSAKA, Japan and CAMBRIDGE, Massachusetts, March 25, 2026 – Takeda (TSE:4502/NYSE:TAK) announced today its Board of Directors approved the next steps in the Company's transformation to strengthen ...
# Takeda Announces Changes to Organizational Structure and Executive Leadership Team for Fiscal Year 2026 to Fuel Speed, Competitiveness and Future Growth “Underpinned by strong values and purpose, ...
# New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 "Narcolepsy type 1 is a 24-hour disease driven by orexin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results